Specialty Endocrinology
-
Featured
Mass General Researchers Develop New Oral Compound for Osteoporosis Prevention and Treatment
Massachusetts General Hospital researchers have identified a new compound that increased bone formation and bone mass when given orally to mice. Their findings may lead to a new, more convenient therapy for the prevention and treatment of osteoporosis.
-
Bionic Pancreas Improves Glycemic Control in Patients With Cystic Fibrosis-related Diabetes
Melissa Putman, MD, Jordan Sherwood, MD, and colleagues report that the insulin-only iLet bionic pancreas improved glucose control in patients with cystic fibrosis-related diabetes (CFRD) compared to usual care, without an increase in continuous glucose monitoring-measured hypoglycemia.
-
Continuous Glucose Monitoring Predicts Long-term Nutritional Outcomes in Adults With Cystic Fibrosis
Melissa S. Putman, MD, and colleagues correlated findings on continuous glucose monitoring with a decline in body weight and a decline in body mass index over one year in adults with cystic fibrosis. Their data also suggest advanced glycation end products may represent a useful marker in this population.
-
In Utero Exposure to SARS-CoV-2 May Increase the Risk of Cardiometabolic Disease
Massachusetts General Hospital researchers found that infants who have in utero exposure to maternal SARS-CoV-2 exhibit lower birth weight followed by accelerated weight gain in the first year of life, a pattern thought to increase the risk of obesity and cardiometabolic disease in childhood and adulthood.
-
After Denosumab Discontinuation, Alendronate Superior to Raloxifene at Maintaining BMD Gains
Massachusetts General Hospital researchers found that for postmenopausal women with osteoporosis who discontinue short-term denosumab treatment and are unable or unwilling to transition to a bisphosphonate, raloxifene may be a suitable alternative, although inferior in maintaining the gain in bone mineral density.
-
Psychological and Behavioral Factors Identified That Predict Success of Lifestyle Interventions for Weight Loss
Massachusetts General Hospital researchers identified improvements in autonomous motivation, dietary self-regulation, and low-fat diet as the most important predictors of weight loss during a two-year lifestyle intervention, but only improvements in low-fat diet and depression were important after a year of follow-up.
Endocrinology Contributors
-
Camille E. Powe, MD
Endocrinologist, Massachusetts General Hospital, Co-Director, Diabetes in Pregnancy Program
Recent Article
Carbohydrate Intake Before Oral Glucose Tolerance Test May Prevent Accurate Diagnosis of Gestational Diabetes
-
Elizabeth A. Lawson, MD
Clinician, Neuroendocrine Unit, Division of Endocrinology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School
Recent Article
Cholecystokinin Elevation Observed in Youth With Avoidant/Restrictive Food Intake Disorder -
Joel S. Finkelstein, MD
Endocrinologist, Massachusetts General Hospital, Associate Director, Bone Density Center, Endocrine Unit, Massachusetts General Hospital
Recent Article
Ivacaftor Improves Skeletal Outcomes in Patients with Cystic Fibrosis -
Jose C. Florez, MD, PhD
Chief, Diabetes Unit, Endocrine Division, John T. Potts Jr., MD Endowed Chair in Medicine, Massachusetts General Hospital, Professor of Medicine, Harvard Medical School
Recent Article
Newly Identified Genetic Variant Has Substantial Effect on Risk of Type 2 Diabetes
-
Melissa S. Putman, MD
Endocrinologist, Massachusetts General Hospital, Assistant Professor of Pediatrics, Harvard Medical School
Recent Article
Bionic Pancreas Improves Glycemic Control in Patients With Cystic Fibrosis-related Diabetes -
Steven Kyle Grinspoon, MD
Chief, Metabolism Unit, Massachusetts General Hospital, Director, Nutrition Obesity Research Center, Harvard
Recent Article
Diet Quality Is Suboptimal or Poor in Large Proportion of Global Population With HIV
Endocrinology Division
The Endocrinology Division at Massachusetts General Hospital offers a comprehensive integrated program of clinical services for both primary and tertiary care of adults with endocrine disorders.